NCT05483868 - A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions

Non-muscle-invasive Bladder CancerNon-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCGNMIBCNon-Muscle Invasive Bladder CarcinomaNon-Muscle Invasive Bladder NeoplasmsNon-Muscle Invasive Bladder Urothelial CarcinomaUrothelial Carcinoma Bladder

Interventions

DRUG

AU-011

Administration of AU-011 intratumorally and intramurally

COMBINATION_PRODUCT

AU-011 in Combination with Medical Laser Adminstration

AU-011 Intratumorally and Intramurally

COMBINATION_PRODUCT

AU-011 in Combination with Medical Laser Administration

AU-011 Intratumorally

Trial Locations (10)

10461

RECRUITING

Montefiore Medical Center, The Bronx

29272

RECRUITING

Carolina Urologic Research Center, Myrtle Beach

37209

SUSPENDED

Urology Associates, P.C., Nashville

72211

TERMINATED

Arkansas Urology, Little Rock

75251

RECRUITING

Urology Clinics of North Texas, Dallas

77030

RECRUITING

Baylor College of Medicine, Houston

78229

RECRUITING

The University of Texas San Antonio, San Antonio

RECRUITING

Urology San Antonio/USA Clinical Trials, San Antonio

78240

RECRUITING

The Urology Place, San Antonio

90404

RECRUITING

Saint John's Cancer Institute, Santa Monica